title: Sequential administration of human and porcine factor VIII for surgical treatment of a parotid tumour in a patient with a factor VIII inhibitor.
abstract: The sequential use of human and porcine factor VIII for the treatment of a patient with a moderately high titre (38 Bethesda units) factor VIII inhibitor enabled us to provide adequate haemostatic cover for 17 days. In this period a pleomorphic adenoma of the parotid gland was removed. Bleeding did not occur and wound healing was uneventful.
authors.forename: E
authors.initials: E
authors.lastname: Briët
authors.forename: F W
authors.initials: FW
authors.lastname: van der Meer
authors.forename: C J
authors.initials: CJ
authors.lastname: van Dijk-van Kempen
authors.forename: P H
authors.initials: PH
authors.lastname: Schmidt
authors.forename: F W
authors.initials: FW
authors.lastname: Otten
authors.forename: K
authors.initials: K
authors.lastname: Meyer
authors.forename: A W
authors.initials: AW
authors.lastname: Broekmans
mesh_terms: D008949:Adenoma, Pleomorphic / Q000601:surgery*; D000328:Adult; D000818:Animals; D005169:Factor VIII / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D005340:Fibrinogen / Q000009:adverse effects; D006467:Hemophilia A / Q000097:blood / Q000628:therapy*; D006801:Humans; D007263:Infusions, Parenteral; D007518:Isoantibodies; D008297:Male; D010307:Parotid Neoplasms / Q000601:surgery*; D013552:Swine
chemical_list: D007518:Isoantibodies; C026912:cryoprecipitate coagulum; D005169:Factor VIII; D005340:Fibrinogen